Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The latest trading day saw Moderna (MRNA) settling at $85.95, representing a +0.68% change from its previous close.

Here's Why Moderna (MRNA) Gained But Lagged the Market Today

First Solar

Tesla

In a time when AI is a friend and a guide through complex financial markets, AI-driven insights provide delight and optimism. Let us begin a deep dive into how ChatGPT, a sophisticated AI model, can go through massive market data and uncover a few stars with fast-growing potential.

ChatGPT Stock Predictions: 3 Companies the AI Bot Thinks Have 10X Potential

Fiverr

Fiverr's betting big on the rapidly growing gig economy. Moderna's deep pipeline will help it recover from its current predicament.

2 Stocks Down 36% or More to Buy and Hold for 10 Years

Amazon

American Express

Bath and Body Works

Best Buy

Blackstone Group

Salesforce

General Electric

Alphabet

Kinder Morgan

Kroger

Eli Lilly

Marathon Oil

Whirlpool

Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a new UBS report says.

Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer

Maravai LifeSciences Holdings

Novavax

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

Moderna shares fell 6% on Friday after a longer-term analysis of a trial indicated a quicker fall in the efficacy of its experimental respiratory syncytial virus (RSV) vaccine.

Moderna shares slide as longer-term data shows quick fall in RSV vaccine efficacy

CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the COVID-19 vaccine." Stéphane Bancel has served as Moderna's Chief Executive Officer since October 2011 and as a member of Moderna's board of directors since March 2011.

Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering

Metagenomi Technologies, a genetic medicines company backed by Moderna , said on Monday it was targeting a valuation of up to $638 million for its initial public offering in New York.

Moderna-backed Metagenomi targets up to $638 mln valuation for US IPO

CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update.

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024

CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune's World's Most Admired Companies list as part of its "All-Star" top-50 companies. This annual list is considered one of the leading measures of corporate reputation among global organizations.

Moderna Named to Fortune's List of World's Most Admired Companies

Medtronic

NVIDIA

A new bull market is here, and this type of environment generally favors growth stocks. Certain companies could get an additional boost thanks to their presence in the ultrahigh-growth market of artificial intelligence.

My Top-5 AI Growth Stocks to Buy Hand Over Fist for 2024

Moderna's shares have plunged with declining demand for its COVID-19 vaccine. Several analysts have renewed optimism about the biotech stock as it expands beyond COVID.

1 Growth Stock Down 79% That's a Screaming Buy Right Now, According to Several Wall Street Analysts

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

General Motors

Warner Bros Discovery Inc

The broad-based S&P 500 has been Wall Street's top "health" barometer for decades. High-water price targets from a trio of Wall Street analysts imply triple-digit gains to come for three S&P 500 components.

3 S&P 500 Stocks With 127% to 170% Upside in 2024, According to Select Wall Street Analysts

Moderna stock fell after maintaining its 2024 outlook despite beating 2023 sales expectations. Is MRNA stock a buy or a sell right now?

Is Moderna Stock A Buy Or A Sell As Covid-Related Challenges Linger?

Moderna's revenue and earnings dropped off a cliff last year. However, the biotech is close to launching a new product.

1 Stock Down 43% to Buy and Hold for 10 Years

Pfizer

Pfizer is completing its biggest string of product launches ever, which should spur a new era of growth. Moderna expects to soon have a new RSV vaccine on the market, with other products to follow.

Better Bull Market Buy: Pfizer vs. Moderna

Moderna went from being a stock market winner, soaring more than 400%, to a losing stock in recent times. Investors have worried about coronavirus vaccine declines and the biotech company's future revenue picture.

3 Things That Could Help 2023 Loser-Stock Moderna Roar Higher in 2024

Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Asensus Surgical

Editas Medicine

Hologic

Illumina

Johnson & Johnson

Verve Therapeutics

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.

7 Mighty Healthcare Stocks Changing the Game of Medicine

Lumen Technologies

Plug Power

Plug Power's financials are in horrible shape, and a lack of cash is a big concern for investors. Moderna's reliance on COVID and flu revenue could limit any growth it's able to generate ahead.

3 Struggling Businesses Investors Shouldn't Gamble on This Year

Amgen

Centene

Cencora Inc

Catalent

Gilead Sciences

Merck

Regeneron Pharmaceuticals

Viatris

The sector has seen one of the best starts to the year in decades, Goldman says.

10 Healthcare Stocks That Are Heating Up

Amylyx Pharmaceuticals

Boston Scientific

CRISPR Therapeutics

Globus Medical

iRhythm Technologies

Teladoc

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to boil it down to one phrase, it would be permanent relevance.

7 Healthcare Stocks Taking Medicine to the Next Level

Enphase Energy

Owning powerhouse stocks can add significant value to your portfolio. Megatrends are those that are shaping or will shape society in significant ways.

3 Megatrend Stocks that Will Revolutionize Your Portfolio

Apple

Chewy

A well-thought-out portfolio could help you win this year and over time. It's crucial to diversify your investments and invest for the long term.

The Best Places to Invest $100,000 in 2024

News for Moderna Stock (MRNA)